A Multi-country, Post Marketing Observational Study of DME Patients with Suboptimal Response to anti-VEGF who are initiated with Dexamethasone intravitreal implant (DEX-I)
To describe patient characteristics and anti-VEGF treatment patterns and evaluate the effectiveness of early vs. late DEX-I initiation in DME patients with suboptimal response to anti-VEGF therapy.